{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:38:40Z","timestamp":1792795120405,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is closely associated with metabolic conditions such as obesity and diabetes mellitus, which significantly impact human health outcomes. The impaired lipid profiles observed in NAFLD individuals can further contribute to cardiovascular events. Despite the high prevalence of NAFLD, there is currently no confirmed intervention approved for its treatment. This study aimed to summarize the results of meta-analysis studies of randomized control trials assessing the impact of gut microbial therapy (probiotics, synbiotics, and prebiotics) on the lipid profile of individuals with NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library up to November 1, 2022. Meta-analyses surveying the impact of microbial therapy on lipid profile parameters (triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC)) in the NAFLD population were included in our umbrella review. The final effect size (ES) was estimated, and sensitivity and subgroup analyses were performed to explore heterogeneity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifteen studies were included in this umbrella review. Microbial therapy significantly reduced TG (ES\u2009\u2212\u20090.31, 95% CI\u2009\u2212\u20090.51,\u2009\u2212\u20090.11, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), TC (ES\u2009\u2212\u20091.04, 95% CI\u2009\u2212\u20091.46,\u2009\u2212\u20090.61, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and LDL (ES\u2009\u2212\u20090.77, 95% CI\u2009\u2212\u20091.15,\u2009\u2212\u20090.39, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) in individuals with NAFLD. However, the effect on HDL was not statistically significant (ES\u2009\u2212\u20090.06; 95% CI\u2009\u2212\u20090.19, 0.07, <jats:italic>P<\/jats:italic>\u2009=\u20090.39).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Considering the absence of approved treatments for NAFLD and the promising role of microbial therapies in improving the three lipid profiles components in individuals with NAFLD, the use of these agents as alternative treatment options could be recommended. The findings underscore the potential of gut microbial therapy, including probiotics, synbiotics, and prebiotics, in managing NAFLD and its associated metabolic complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>PROSPERO (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022346998\">CRD42022346998<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13643-023-02299-x","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:02:41Z","timestamp":1692633761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-6745","authenticated-orcid":false,"given":"Amirhossein","family":"Naghipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Amini-Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Orang Gorabzarmakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Shahdkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Alipourfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Momayez","family":"Sanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"issue":"4","key":"2299_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cld.81","volume":"1","author":"P Puri","year":"2012","unstructured":"Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. Clinical liver disease. 2012;1(4):99\u2013103. https:\/\/doi.org\/10.1002\/cld.81.","journal-title":"Clinical liver disease"},{"issue":"6","key":"2299_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","volume":"7","author":"SM Abd El-Kader","year":"2015","unstructured":"Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol. 2015;7(6):846\u201358. https:\/\/doi.org\/10.4254\/wjh.v7.i6.846.","journal-title":"World J Hepatol"},{"issue":"2","key":"2299_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0035-1550065","volume":"35","author":"P Angulo","year":"2015","unstructured":"Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis. 2015;35(2):132\u201345. https:\/\/doi.org\/10.1055\/s-0035-1550065.","journal-title":"Semin Liver Dis"},{"key":"2299_CR4","first-page":"29","volume":"511","author":"J Cooper","year":"2021","unstructured":"Cooper J, Baumgartner K, Smith A, St LJ. Liver disease: nonalcoholic fatty liver disease. FP essentials. 2021;511:29\u201335.","journal-title":"FP essentials"},{"issue":"4","key":"2299_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jamcollsurg.2010.01.020","volume":"210","author":"AD Tevar","year":"2010","unstructured":"Tevar AD, Clarke C, Wang J, et al. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg. 2010;210(4):515\u201326. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2010.01.020.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2299_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mpmed.2006.11.010","volume":"35","author":"J Collier","year":"2007","unstructured":"Collier J. Non-alcoholic fatty liver disease. Medicine. 2007;35(2):86\u20138.","journal-title":"Medicine"},{"issue":"1","key":"2299_CR7","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9.","journal-title":"Hippokratia"},{"issue":"2","key":"2299_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1017\/S0029665110000030","volume":"69","author":"JB Moore","year":"2010","unstructured":"Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proceedings of the Nutrition Society. 2010;69(2):211\u201320.","journal-title":"Proceedings of the Nutrition Society"},{"key":"2299_CR9","doi-asserted-by":"publisher","unstructured":"Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.002.","DOI":"10.1016\/j.cgh.2021.12.002"},{"issue":"5","key":"2299_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis. 2021;17(5):365\u201370. https:\/\/doi.org\/10.1002\/cld.1061.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"2299_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/apt.15416","volume":"50","author":"N Koopman","year":"2019","unstructured":"Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50(6):628\u201339.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2299_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2016.0109","volume":"23","author":"S Sookoian","year":"2017","unstructured":"Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23(1):1.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2299_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3945\/an.116.013151","volume":"8","author":"Z Mokhtari","year":"2017","unstructured":"Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240\u201352.","journal-title":"Adv Nutr"},{"issue":"11","key":"2299_CR14","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/nu11112642","volume":"11","author":"M Meroni","year":"2019","unstructured":"Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients. 2019;11(11):2642.","journal-title":"Nutrients"},{"issue":"11","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tem.2013.05.009","volume":"24","author":"AR Moschen","year":"2013","unstructured":"Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24(11):537\u201345.","journal-title":"Trends Endocrinol Metab"},{"issue":"7","key":"2299_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, et al. The gut\u2013liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2299_CR17","doi-asserted-by":"publisher","first-page":"204062232110486","DOI":"10.1177\/20406223211048649","volume":"12","author":"Y Cao","year":"2021","unstructured":"Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Therapeutic Adv Chronic Dis. 2021;12:20406223211048650. https:\/\/doi.org\/10.1177\/20406223211048649.","journal-title":"Therapeutic Adv Chronic Dis"},{"issue":"1","key":"2299_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/21655979.2021.1933302","volume":"12","author":"C Ma","year":"2021","unstructured":"Ma C, Yan K, Wang Z, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021;12(1):2187\u2013202. https:\/\/doi.org\/10.1080\/21655979.2021.1933302.","journal-title":"Bioengineered"},{"issue":"9","key":"2299_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612. https:\/\/doi.org\/10.1038\/s41575-021-00448-y.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"2299_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (Baltimore, MD). 2010;51(2):679\u201389. https:\/\/doi.org\/10.1002\/hep.23280.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"20","key":"2299_CR21","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.12998\/wjcc.v8.i20.4688","volume":"8","author":"U Arslan","year":"2020","unstructured":"Arslan U, Yener\u00e7a\u011f M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020;8(20):4688\u201399. https:\/\/doi.org\/10.12998\/wjcc.v8.i20.4688.","journal-title":"World J Clin Cases"},{"issue":"1","key":"2299_CR22","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9\u201319.","journal-title":"Hippokratia"},{"issue":"1","key":"2299_CR23","doi-asserted-by":"publisher","first-page":"e131523","DOI":"10.5812\/hepatmon-131523","volume":"23","author":"E Amini-Salehi","year":"2023","unstructured":"Amini-Salehi E, Hassanipour S, Joukar F, et al. Risk factors of non-alcoholic fatty liver disease in the iranian adult population: a systematic review and meta-analysis. Systematic Review Hepat Mon. 2023;23(1):e131523. https:\/\/doi.org\/10.5812\/hepatmon-131523.","journal-title":"Systematic Review. Hepat Mon."},{"issue":"1","key":"2299_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12876-021-01720-w","volume":"21","author":"P Phisalprapa","year":"2021","unstructured":"Phisalprapa P, Prasitwarachot R, Kositamongkol C, et al. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol. 2021;21(1):135. https:\/\/doi.org\/10.1186\/s12876-021-01720-w.","journal-title":"BMC Gastroenterol."},{"issue":"6","key":"2299_CR25","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/hep.30094","volume":"68","author":"AM Allen","year":"2018","unstructured":"Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. Claims Database Hepatology (Baltimore, Md). 2018;68(6):2230\u20138. https:\/\/doi.org\/10.1002\/hep.30094.","journal-title":"Claims Database. Hepatology (Baltimore, Md)"},{"issue":"1","key":"2299_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2299_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):1\u20139.","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2299_CR28","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1159\/000495830","volume":"51","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Zheng T, Chen H, et al. Microbial intervention as a novel target in treatment of non-alcoholic fatty liver disease progression. Cell Physiol Biochem. 2018;51(5):2123\u201335. https:\/\/doi.org\/10.1159\/000495830.","journal-title":"Cell Physiol Biochem"},{"key":"2299_CR29","doi-asserted-by":"publisher","unstructured":"Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients. 2019;11(11). https:\/\/doi.org\/10.3390\/nu11112642.","DOI":"10.3390\/nu11112642"},{"issue":"24","key":"2299_CR30","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","volume":"375","author":"SV Lynch","year":"2016","unstructured":"Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369\u201379.","journal-title":"N Engl J Med"},{"key":"2299_CR31","doi-asserted-by":"publisher","unstructured":"Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods (Basel, Switzerland). 2019;8(3). https:\/\/doi.org\/10.3390\/foods8030092.","DOI":"10.3390\/foods8030092"},{"key":"2299_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/10_2008_097","volume":"111","author":"M de Vrese","year":"2008","unstructured":"de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1\u201366. https:\/\/doi.org\/10.1007\/10_2008_097.","journal-title":"Adv Biochem Eng Biotechnol"},{"issue":"3","key":"2299_CR33","doi-asserted-by":"publisher","first-page":"e017995","DOI":"10.1136\/bmjopen-2017-017995","volume":"9","author":"H Koutnikova","year":"2019","unstructured":"Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9(3):e017995.","journal-title":"BMJ Open"},{"key":"2299_CR34","doi-asserted-by":"crossref","unstructured":"Xiao M-W, Lin S-X, Shen Z-H, Luo W-W, Wang X-Y. Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:14845982019.","DOI":"10.1155\/2019\/1484598"},{"issue":"6","key":"2299_CR35","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00394-017-1568-y","volume":"57","author":"S Khalesi","year":"2018","unstructured":"Khalesi S, Johnson DW, Campbell K, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr. 2018;57(6):2037\u201353.","journal-title":"Eur J Nutr"},{"issue":"15","key":"2299_CR36","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","volume":"59","author":"A Hadi","year":"2019","unstructured":"Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Crit Rev Food Sci Nutr. 2019;59(15):2494\u2013505. https:\/\/doi.org\/10.1080\/10408398.2018.1458021.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2299_CR37","doi-asserted-by":"publisher","unstructured":"Stachowska E, Portincasa P, Jamio\u0142-Milc D, Maciejewska-Markiewicz D, Skonieczna-\u017bydecka K. The relationship between prebiotic supplementation and anthropometric and biochemical parameters in patients with NAFLD-A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2020;12(11). https:\/\/doi.org\/10.3390\/nu12113460.","DOI":"10.3390\/nu12113460"},{"key":"2299_CR38","doi-asserted-by":"crossref","unstructured":"Shuster J. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3\/2011. Julian P.T. Higgins and Sally Green, Editors. Res Synth Methods. 2011;2:126\u201330.","DOI":"10.1002\/jrsm.38"},{"issue":"1","key":"2299_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1\u201311.","journal-title":"Syst Rev"},{"key":"2299_CR40","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJRB Shea","year":"2017","unstructured":"Shea BJRB, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008 (https:\/\/amstar.ca\/Amstar_Checklist.php#:~:text=To%20cite%20this%20tool%3A%20Shea,Sep%2021%3B358%3Aj4008).","journal-title":"BMJ."},{"key":"2299_CR41","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Bmj. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"Bmj."},{"issue":"7109","key":"2299_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"3","key":"2299_CR43","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/mpg.0000000000003537","volume":"75","author":"\u039d Gkiourtzis","year":"2022","unstructured":"Gkiourtzis \u039d, Kalopitas G, Vadarlis A, et al. The benefit of probiotics in pediatric nonalcoholic fatty liver disease: a meta-analysis of randomized control trials. J Pediatr Gastroenterol Nutr. 2022;75(3):e31\u20137. https:\/\/doi.org\/10.1097\/mpg.0000000000003537.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2299_CR44","doi-asserted-by":"publisher","first-page":"7888076","DOI":"10.1155\/2022\/7888076","volume":"2022","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wang X, Zhang L, et al. Effect of probiotics therapy on nonalcoholic fatty liver disease. Comput Math Methods Med. 2022;2022:7888076. https:\/\/doi.org\/10.1155\/2022\/7888076.","journal-title":"Comput Math Methods Med"},{"key":"2299_CR45","doi-asserted-by":"publisher","first-page":"862266","DOI":"10.3389\/fpubh.2022.862266","volume":"10","author":"S Li","year":"2022","unstructured":"Li S, Liu J, Wang Z, et al. The promising role of probiotics\/prebiotics\/synbiotics in energy metabolism biomarkers in patients with NAFLD: a systematic review and meta-analysis. Front Public Health. 2022;10:862266. https:\/\/doi.org\/10.3389\/fpubh.2022.862266.","journal-title":"Front Public Health."},{"issue":"12","key":"2299_CR46","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","volume":"15","author":"R Yang","year":"2021","unstructured":"Yang R, Shang J, Zhou Y, Liu W, Tian Y, Shang H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(12):1401\u20139. https:\/\/doi.org\/10.1080\/17474124.2022.2016391.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"2299_CR47","doi-asserted-by":"publisher","first-page":"e017995","DOI":"10.1136\/bmjopen-2017-017995","volume":"9","author":"H Koutnikova","year":"2019","unstructured":"Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9(3):e017995. https:\/\/doi.org\/10.1136\/bmjopen-2017-017995.","journal-title":"BMJ Open."},{"key":"2299_CR48","doi-asserted-by":"publisher","first-page":"1484598","DOI":"10.1155\/2019\/1484598","volume":"2019","author":"MW Xiao","year":"2019","unstructured":"Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:1484598. https:\/\/doi.org\/10.1155\/2019\/1484598.","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"2299_CR49","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1007\/s10620-019-05699-z","volume":"64","author":"L Liu","year":"2019","unstructured":"Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis. Dig Dis Sci. 2019;64(12):3402\u201312. https:\/\/doi.org\/10.1007\/s10620-019-05699-z.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"2299_CR50","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/meg.0000000000001371","volume":"31","author":"MY Khan","year":"2019","unstructured":"Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(6):703\u201315. https:\/\/doi.org\/10.1097\/meg.0000000000001371.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"2299_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","volume":"110","author":"SR Sharpton","year":"2019","unstructured":"Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139\u201349. https:\/\/doi.org\/10.1093\/ajcn\/nqz042.","journal-title":"Am J Clin Nutr"},{"key":"2299_CR52","doi-asserted-by":"publisher","first-page":"175628481987804","DOI":"10.1177\/1756284819878046","volume":"12","author":"Y Tang","year":"2019","unstructured":"Tang Y, Huang J, Zhang WY, et al. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2019;12:1756284819878046. https:\/\/doi.org\/10.1177\/1756284819878046.","journal-title":"Therap Adv Gastroenterol"},{"issue":"11","key":"2299_CR53","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","volume":"76","author":"BR Loman","year":"2018","unstructured":"Loman BR, Hern\u00e1ndez-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 2018;76(11):822\u201339. https:\/\/doi.org\/10.1093\/nutrit\/nuy031.","journal-title":"Nutr Rev"},{"key":"2299_CR54","doi-asserted-by":"publisher","unstructured":"A SL, D VR, Manohar T, A AL. Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Euroasian J Hepatogastroenterol. 2017;7(2):130\u2013137. https:\/\/doi.org\/10.5005\/jp-journals-10018-1233.","DOI":"10.5005\/jp-journals-10018-1233"},{"issue":"12","key":"2299_CR55","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/hepr.12671","volume":"46","author":"X Gao","year":"2016","unstructured":"Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatol Res. 2016;46(12):1226\u201333. https:\/\/doi.org\/10.1111\/hepr.12671.","journal-title":"Hepatol Res"},{"issue":"40","key":"2299_CR56","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.3748\/wjg.v19.i40.6911","volume":"19","author":"YY Ma","year":"2013","unstructured":"Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911\u20138. https:\/\/doi.org\/10.3748\/wjg.v19.i40.6911.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2299_CR57","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/ptr.7383","volume":"36","author":"J Mao","year":"2022","unstructured":"Mao J, Zhan H, Meng F, et al. Costunolide protects against alcohol-induced liver injury by regulating gut microbiota, oxidative stress and attenuating inflammation in vivo and in vitro. Phytother Res. 2022;36(3):1268\u201383. https:\/\/doi.org\/10.1002\/ptr.7383.","journal-title":"Phytother Res"},{"issue":"3","key":"2299_CR58","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1080\/21655979.2022.2037374","volume":"13","author":"G Jiang","year":"2022","unstructured":"Jiang G, Sun C, Wang X, et al. Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification. Bioengineered. 2022;13(3):5216\u201335. https:\/\/doi.org\/10.1080\/21655979.2022.2037374.","journal-title":"Bioengineered"},{"key":"2299_CR59","doi-asserted-by":"publisher","unstructured":"Xu S, Jiang X, Jia X, et al. Silymarin modulates microbiota in the gut to improve the health of sow from late gestation to lactation. Animals (Basel). 2022;12(17). https:\/\/doi.org\/10.3390\/ani12172202.","DOI":"10.3390\/ani12172202"},{"key":"2299_CR60","doi-asserted-by":"publisher","first-page":"104711","DOI":"10.1016\/j.jff.2021.104711","volume":"86","author":"C Wang","year":"2021","unstructured":"Wang C, Li S, Xue P, et al. The effect of probiotic supplementation on lipid profiles in adults with overweight or obesity: A meta-analysis of randomized controlled trials. Journal of Functional Foods. 2021;86:104711. https:\/\/doi.org\/10.1016\/j.jff.2021.104711.","journal-title":"Journal of Functional Foods."},{"issue":"12","key":"2299_CR61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.medcli.2018.09.007","volume":"152","author":"R Mo","year":"2019","unstructured":"Mo R, Zhang X, Yang Y. Effect of probiotics on lipid profiles in hypercholesterolaemic adults: a meta-analysis of randomized controlled trials. Med Clin (Barc). 2019;152(12):473\u201381. https:\/\/doi.org\/10.1016\/j.medcli.2018.09.007.","journal-title":"Med Clin (Barc)"},{"key":"2299_CR62","doi-asserted-by":"publisher","first-page":"104177","DOI":"10.1016\/j.jff.2020.104177","volume":"74","author":"J Jiang","year":"2020","unstructured":"Jiang J, Wu C, Zhang C, et al. Effects of probiotic supplementation on cardiovascular risk factors in hypercholesterolemia: A systematic review and meta-analysis of randomized clinical trial. J Functional Foods. 2020;74:104177. https:\/\/doi.org\/10.1016\/j.jff.2020.104177.","journal-title":"J Functional Foods."},{"issue":"10","key":"2299_CR63","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","volume":"85","author":"V Behrouz","year":"2020","unstructured":"Behrouz V, Aryaeian N, Zahedi MJ, Jazayeri S. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. J Food Sci. 2020;85(10):3611\u20137. https:\/\/doi.org\/10.1111\/1750-3841.15367.","journal-title":"J Food Sci"},{"issue":"43","key":"2299_CR64","doi-asserted-by":"publisher","first-page":"e1714","DOI":"10.1097\/md.0000000000001714","volume":"94","author":"YA Cho","year":"2015","unstructured":"Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(43):e1714. https:\/\/doi.org\/10.1097\/md.0000000000001714.","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"2299_CR65","doi-asserted-by":"publisher","first-page":"e0178868","DOI":"10.1371\/journal.pone.0178868","volume":"12","author":"Y Wu","year":"2017","unstructured":"Wu Y, Zhang Q, Ren Y, Ruan Z. Effect of probiotic Lactobacillus on lipid profile: a systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017;12(6):e0178868. https:\/\/doi.org\/10.1371\/journal.pone.0178868.","journal-title":"PLoS One."},{"key":"2299_CR66","doi-asserted-by":"publisher","first-page":"775216","DOI":"10.3389\/fnut.2021.775216","volume":"8","author":"B Pan","year":"2021","unstructured":"Pan B, Liu X, Shi J, et al. A meta-analysis of microbial therapy against metabolic syndrome: evidence from randomized controlled trials. Front Nutr. 2021;8:775216. https:\/\/doi.org\/10.3389\/fnut.2021.775216.","journal-title":"Front Nutr."},{"issue":"1","key":"2299_CR67","doi-asserted-by":"publisher","first-page":"11787","DOI":"10.1038\/s41598-020-68440-1","volume":"10","author":"T Kocsis","year":"2020","unstructured":"Kocsis T, Moln\u00e1r B, N\u00e9meth D, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Sci Rep. 2020;10(1):11787. https:\/\/doi.org\/10.1038\/s41598-020-68440-1.","journal-title":"Sci Rep."},{"issue":"8","key":"2299_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.medcli.2016.11.036","volume":"148","author":"YM Hu","year":"2017","unstructured":"Hu YM, Zhou F, Yuan Y, Xu YC. Effects of probiotics supplement in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Med Clin (Barc). 2017;148(8):362\u201370. https:\/\/doi.org\/10.1016\/j.medcli.2016.11.036. (Efectos del suplemento de probi\u00f3ticos en pacientes con diabetes mellitus tipo 2: metaan\u00e1lisis de ensayos aleatorizados).","journal-title":"Med Clin (Barc)."},{"issue":"2","key":"2299_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","volume":"47","author":"JM Ridlon","year":"2006","unstructured":"Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241\u201359. https:\/\/doi.org\/10.1194\/jlr.R500013-JLR200.","journal-title":"J Lipid Res"},{"issue":"1","key":"2299_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","volume":"3","author":"P G\u00e9rard","year":"2013","unstructured":"G\u00e9rard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 2013;3(1):14\u201324. https:\/\/doi.org\/10.3390\/pathogens3010014.","journal-title":"Pathogens"},{"key":"2299_CR71","doi-asserted-by":"publisher","first-page":"902917","DOI":"10.1155\/2012\/902917","volume":"2012","author":"M Kumar","year":"2012","unstructured":"Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917. https:\/\/doi.org\/10.1155\/2012\/902917.","journal-title":"Exp Diabetes Res."},{"issue":"1","key":"2299_CR72","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1017\/s0007114511000237","volume":"106","author":"JM Lecerf","year":"2011","unstructured":"Lecerf JM, de Lorgeril M. Dietary cholesterol: from physiology to cardiovascular risk. Br J Nutr. 2011;106(1):6\u201314. https:\/\/doi.org\/10.1017\/s0007114511000237.","journal-title":"Br J Nutr"},{"issue":"1","key":"2299_CR73","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mnfr.201400548","volume":"59","author":"N Ishimwe","year":"2015","unstructured":"Ishimwe N, Daliri EB, Lee BH, Fang F, Du G. The perspective on cholesterol-lowering mechanisms of probiotics. Mol Nutr Food Res. 2015;59(1):94\u2013105. https:\/\/doi.org\/10.1002\/mnfr.201400548.","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"2299_CR74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/joe-09-0271","volume":"204","author":"C Zhao","year":"2010","unstructured":"Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol. 2010;204(3):233\u201340. https:\/\/doi.org\/10.1677\/joe-09-0271.","journal-title":"J Endocrinol"},{"issue":"25","key":"2299_CR75","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.2174\/092986706778521814","volume":"13","author":"F Fava","year":"2006","unstructured":"Fava F, Lovegrove JA, Gitau R, Jackson KG, Tuohy KM. The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. Curr Med Chem. 2006;13(25):3005\u201321. https:\/\/doi.org\/10.2174\/092986706778521814.","journal-title":"Curr Med Chem"},{"issue":"4","key":"2299_CR76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0958-6946(02)00174-7","volume":"13","author":"YT Ahn","year":"2003","unstructured":"Ahn YT, Kim GB, Lim KS, Baek YJ, Kim HU. Deconjugation of bile salts by Lactobacillus acidophilus isolates. Int Dairy J. 2003;13(4):303\u201311. https:\/\/doi.org\/10.1016\/s0958-6946(02)00174-7.","journal-title":"Int Dairy J."},{"issue":"9","key":"2299_CR77","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.3390\/ijms10093755","volume":"10","author":"HS Lye","year":"2009","unstructured":"Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10(9):3755\u201375. https:\/\/doi.org\/10.3390\/ijms10093755.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2299_CR78","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3168\/jds.2009-2574","volume":"93","author":"HS Lye","year":"2010","unstructured":"Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci. 2010;93(4):1383\u201392. https:\/\/doi.org\/10.3168\/jds.2009-2574.","journal-title":"J Dairy Sci"},{"issue":"3","key":"2299_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.idairyj.2009.10.003","volume":"20","author":"H-S Lye","year":"2010","unstructured":"Lye H-S, Rahmat-Ali G, Liong M-T. Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int Dairy J. 2010;20(3):169\u201375. https:\/\/doi.org\/10.1016\/j.idairyj.2009.10.003.","journal-title":"Int Dairy J."},{"issue":"32","key":"2299_CR80","doi-asserted-by":"publisher","first-page":"33586","DOI":"10.1074\/jbc.M405817200","volume":"279","author":"HR Davis Jr","year":"2004","unstructured":"Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586\u201392. https:\/\/doi.org\/10.1074\/jbc.M405817200.","journal-title":"J Biol Chem"},{"issue":"5661","key":"2299_CR81","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201\u20134. https:\/\/doi.org\/10.1126\/science.1093131.","journal-title":"Science"},{"issue":"5","key":"2299_CR82","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3168\/jds.2012-6371","volume":"96","author":"Y Huang","year":"2013","unstructured":"Huang Y, Wu F, Wang X, Sui Y, Yang L, Wang J. Characterization of Lactobacillus plantarum Lp27 isolated from Tibetan kefir grains: a potential probiotic bacterium with cholesterol-lowering effects. J Dairy Sci. 2013;96(5):2816\u201325. https:\/\/doi.org\/10.3168\/jds.2012-6371.","journal-title":"J Dairy Sci"},{"issue":"4","key":"2299_CR83","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1017\/s0007114509991991","volume":"103","author":"Y Huang","year":"2010","unstructured":"Huang Y, Zheng Y. The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the down-regulation of Niemann-Pick C1-like 1 in Caco-2 cells. Br J Nutr. 2010;103(4):473\u20138. https:\/\/doi.org\/10.1017\/s0007114509991991.","journal-title":"Br J Nutr"},{"issue":"2","key":"2299_CR84","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1017\/s0954422410000247","volume":"23","author":"P Guilloteau","year":"2010","unstructured":"Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2010;23(2):366\u201384. https:\/\/doi.org\/10.1017\/s0954422410000247.","journal-title":"Nutr Res Rev"},{"issue":"6","key":"2299_CR85","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ajcn\/61.6.1241","volume":"61","author":"TM Wolever","year":"1995","unstructured":"Wolever TM, Spadafora PJ, Cunnane SC, Pencharz PB. Propionate inhibits incorporation of colonic [1,2\u201313C]acetate into plasma lipids in humans. Am J Clin Nutr. 1995;61(6):1241\u20137. https:\/\/doi.org\/10.1093\/ajcn\/61.6.1241.","journal-title":"Am J Clin Nutr"},{"issue":"18","key":"2299_CR86","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.1007\/s00253-013-5088-2","volume":"97","author":"A Bordoni","year":"2013","unstructured":"Bordoni A, Amaretti A, Leonardi A, et al. Cholesterol-lowering probiotics: in vitro selection and in vivo testing of bifidobacteria. Appl Microbiol Biotechnol. 2013;97(18):8273\u201381. https:\/\/doi.org\/10.1007\/s00253-013-5088-2.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"2299_CR87","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/mnfr.201300224","volume":"58","author":"CS Stancu","year":"2014","unstructured":"Stancu CS, Sanda GM, Deleanu M, Sima AV. Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters. Mol Nutr Food Res. 2014;58(3):559\u201368. https:\/\/doi.org\/10.1002\/mnfr.201300224.","journal-title":"Mol Nutr Food Res"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-023-02299-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:40:15Z","timestamp":1700412015000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-023-02299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1186\/s13643-023-02299-x","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}